Indication intelligence, analysis and sector perception

Cellectis S.A. (CLLS) cancels $100 M ADS (American Depositary Shares) offering

December 15, 2020 8:42pm

CLLS has withdrawn the proposed underwritten offering of American Depositary Shares (“ADS”) due to market conditions.

CLLS also believes that it is not in the best interest of its stockholders to raise the equity capital in the current market environment.

NO numbers ...

CLLS canceled an offering,of an underwritten public offering of $100 million of its American Depositary Shares (“ADS”), each representing one ordinary share of Cellectis.

The Bottom Line: Stats ...

52-week change: +99.68%
52-week high: $32.23
52-week low: $7.32
Shares outstanding: 42.49 M
Float: 26.21 M
Institutional holdings: 33.87%
Share short (11/30) 911.24K
Cash: $281.78 M
Total cash per share: $6.63
Total debt: $71.69$

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.